Top-Rated Dividend StocksTop-Rated DividendNASDAQ:RPRX Royalty Pharma (RPRX) Stock Price, News & Analysis $28.79 +0.11 (+0.38%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$28.69▼$29.0750-Day Range$25.63▼$28.7952-Week Range$25.20▼$31.66Volume2.48 million shsAverage Volume2.30 million shsMarket Capitalization$17.20 billionP/E Ratio21.49Dividend Yield2.92%Price Target$41.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Royalty Pharma alerts: Email Address Royalty Pharma MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside45.2% Upside$41.80 Price TargetShort InterestHealthy4.29% of Float Sold ShortDividend StrengthModerateBased on Four FactorsSustainability-2.25Upright™ Environmental ScoreNews Sentiment0.99Based on 9 Articles This WeekInsider TradingN/AProj. Earnings Growth8.73%From $4.01 to $4.36 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.90 out of 5 starsFinance Sector22nd out of 898 stocksPharmaceutical Preparations Industry7th out of 436 stocks 3.4 Analyst's Opinion Consensus RatingRoyalty Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRoyalty Pharma has only been the subject of 2 research reports in the past 90 days.Read more about Royalty Pharma's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.29% of the float of Royalty Pharma has been sold short.Short Interest Ratio / Days to CoverRoyalty Pharma has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Royalty Pharma has recently decreased by 2.43%, indicating that investor sentiment is improving. Previous Next 2.5 Dividend Strength Dividend YieldRoyalty Pharma pays a meaningful dividend of 2.93%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthRoyalty Pharma does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Royalty Pharma is 62.69%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Royalty Pharma will have a dividend payout ratio of 19.27% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend.Read more about Royalty Pharma's dividend. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRoyalty Pharma has received a 47.64% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Rotavirus vaccine", "HIV medication", "Breast cancer medication", "Prostate cancer medication", "Rheumatoid arthritis medication", and "Multiple myeloma medication" products. See details.Environmental SustainabilityThe Environmental Impact score for Royalty Pharma is -2.25. Previous Next 3.9 News and Social Media Coverage News SentimentRoyalty Pharma has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Finance companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Royalty Pharma this week, compared to 4 articles on an average week.Search Interest14 people have searched for RPRX on MarketBeat in the last 30 days. This is an increase of 8% compared to the previous 30 days.MarketBeat Follows15 people have added Royalty Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Royalty Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders18.90% of the stock of Royalty Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.35% of the stock of Royalty Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Royalty Pharma's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Royalty Pharma are expected to grow by 8.73% in the coming year, from $4.01 to $4.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Royalty Pharma is 21.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.27.Price to Earnings Ratio vs. SectorThe P/E ratio of Royalty Pharma is 21.49, which means that it is trading at a less expensive P/E ratio than the Finance sector average P/E ratio of about 44.32.Price to Earnings Growth RatioRoyalty Pharma has a PEG Ratio of 3.77. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRoyalty Pharma has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Royalty Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…Check out the new "Crypto Bull Run Millionaire Blueprint" now! About Royalty Pharma Stock (NASDAQ:RPRX)Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.Read More RPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RPRX Stock News HeadlinesJuly 24 at 12:24 PM | msn.comEther's BTC-Denominated Price Flirts With 9-Year-Long Trendline Support: Technical AnalysisJuly 24 at 8:30 AM | globenewswire.comRoyalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human CapitalJuly 27, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.July 21, 2024 | finance.yahoo.comRoyalty Pharma (NASDAQ:RPRX) Is Due To Pay A Dividend Of $0.21July 21, 2024 | americanbankingnews.comRoyalty Pharma plc (NASDAQ:RPRX) Receives Average Recommendation of "Moderate Buy" from BrokeragesJuly 19, 2024 | americanbankingnews.comRoyalty Pharma plc Declares Quarterly Dividend of $0.21 (NASDAQ:RPRX)July 19, 2024 | globenewswire.comRoyalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024July 17, 2024 | globenewswire.comRoyalty Pharma Declares Third Quarter 2024 DividendJuly 27, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.July 2, 2024 | insidermonkey.comIs Royalty Pharma plc (RPRX) a Good Stock to Buy Now?June 24, 2024 | investorplace.com7 Biotech Stocks to Buy on the Dip: June 2024June 12, 2024 | benzinga.comWall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend YieldsJune 5, 2024 | investorplace.comJune's Biotech Boom: 3 Stocks to Buy for a Summertime SurgeJune 4, 2024 | globenewswire.comRoyalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceJune 3, 2024 | globenewswire.comRoyalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured NotesMay 29, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Merus (MRUS), Royalty Pharma (RPRX)May 28, 2024 | msn.comWhy Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?May 28, 2024 | globenewswire.comRoyalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 MillionSee More Headlines Receive RPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Ex-Dividend for 6/14 Dividend5/16/2024Dividend Payable6/14/2024Today7/27/2024Next Earnings (Confirmed)8/08/2024Ex-Dividend for 9/13 Dividend8/16/2024Dividend Payable9/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorFinance Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RPRX CUSIP76028H20 CIK897075 Webwww.royaltypharma.com Phone212-883-0200FaxN/AEmployees80Year Founded1996Price Target and Rating Average Stock Price Target$41.80 High Stock Price Target$51.00 Low Stock Price Target$28.00 Potential Upside/Downside+45.2%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$1.34 Trailing P/E Ratio21.49 Forward P/E Ratio7.18 P/E Growth3.77Net Income$1.13 billion Net Margins35.70% Pretax Margin53.03% Return on Equity22.94% Return on Assets13.78% Debt Debt-to-Equity Ratio0.62 Current Ratio12.52 Quick Ratio12.52 Sales & Book Value Annual Sales$2.36 billion Price / Sales7.30 Cash Flow$4.58 per share Price / Cash Flow6.28 Book Value$16.88 per share Price / Book1.71Miscellaneous Outstanding Shares597,440,000Free Float484,521,000Market Cap$17.20 billion OptionableOptionable Beta0.46 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Pablo Gerardo Legorreta (Age 59)Founder, Chairman of the Board & CEO Mr. Terrance P. CoyneExecutive VP & CFOMr. George Wingate Lloyd (Age 64)Executive VP of Investments & Chief Legal Officer Comp: $4.56MMr. Christopher Hite (Age 56)Vice Chairman & Executive VP Comp: $4.56MDr. Marshall Jonathan Urist M.D. (Age 48)Ph.D., Executive Vice President of Research & Investments Comp: $4.56MMr. Arthur Richard McGivern J.D.Executive Vice President of Investments & General CounselMr. Ashwin Pai M.D.Executive Vice President of InvestmentsMs. Kristin Stafford (Age 42)Senior VP & Chief Accounting Officer Mr. Eric Cornelius SchneiderSenior VP & Chief Technology OfficerDr. James Folmar Reddoch Ph.D. (Age 54)Executive VP of Investments & Chief Scientific Officer Comp: $3.4MMore ExecutivesKey CompetitorsHorizon Therapeutics PublicNASDAQ:HZNPJazz PharmaceuticalsNASDAQ:JAZZPerrigoNYSE:PRGOCorcept TherapeuticsNASDAQ:CORTSupernus PharmaceuticalsNASDAQ:SUPNView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 86,248 shares on 7/26/2024Ownership: 0.257%Allspring Global Investments Holdings LLCBought 308,102 shares on 7/26/2024Ownership: 0.052%State of Michigan Retirement SystemBought 4,800 shares on 7/26/2024Ownership: 0.003%Baillie Gifford & Co.Sold 310,033 shares on 7/25/2024Ownership: 2.737%Overbrook Management CorpSold 8,937 shares on 7/25/2024Ownership: 0.034%View All Insider TransactionsView All Institutional Transactions Should I Buy Royalty Pharma Stock? RPRX Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Royalty Pharma plc: Royalty Pharma plc has a strong track record of consistent dividend payments, providing investors with a reliable income stream. The company has a solid net margin of 35.70%, indicating efficient management of costs and profitability. Analysts have set an average target price of $43.00 for Royalty Pharma plc, suggesting potential for stock price appreciation. Royalty Pharma plc operates in the biopharmaceutical industry, which is known for its potential for high growth and innovation. With a payout ratio of 62.69%, Royalty Pharma plc has room for dividend growth while maintaining financial stability. Cons Investors should be bearish about investing in Royalty Pharma plc for these reasons: Recent analyst downgrades and lowered price targets may indicate concerns about the company's future performance. The stock price of Royalty Pharma plc has been trading lower, indicating potential market sentiment shifts or company-specific challenges. UBS Group recently downgraded Royalty Pharma from a "buy" to a "neutral" rating, signaling a shift in analyst sentiment. Market conditions in the biopharmaceutical industry can be volatile, impacting the company's revenue and profitability. Royalty Pharma plc's price-to-earnings-growth ratio of 3.51 may suggest that the stock is currently overvalued relative to its growth prospects. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, July 6, 2024. Please send any questions or comments about these Royalty Pharma pros and cons to contact@marketbeat.com. RPRX Stock Analysis - Frequently Asked Questions How have RPRX shares performed this year? Royalty Pharma's stock was trading at $28.09 at the start of the year. Since then, RPRX shares have increased by 2.5% and is now trading at $28.79. View the best growth stocks for 2024 here. How were Royalty Pharma's earnings last quarter? Royalty Pharma plc (NASDAQ:RPRX) issued its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.02. The biopharmaceutical company had revenue of $568 million for the quarter, compared to the consensus estimate of $671.45 million. Royalty Pharma had a net margin of 35.70% and a trailing twelve-month return on equity of 22.94%. When did Royalty Pharma IPO? Royalty Pharma (RPRX) raised $1.9 billion in an initial public offering on Tuesday, June 16th 2020. The company issued 70,000,000 shares at $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank served as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers. Who are Royalty Pharma's major shareholders? Royalty Pharma's top institutional investors include Baillie Gifford & Co. (2.74%), Swedbank AB (1.81%), Bank of New York Mellon Corp (0.26%) and Sumitomo Mitsui Trust Holdings Inc. (0.17%). Insiders that own company stock include 1978 Sicaf Sif SA Gg, 1978 Sicaf Sif SA - Gg St Gg, Mario Germano Giuliani, Avara Management Ltd, Terrance P Coyne, James F Reddoch, Pablo G Legorreta, George W Lloyd, Marshall Urist, Rory B Riggs and Henry A Fernandez. View institutional ownership trends. How do I buy shares of Royalty Pharma? Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Royalty Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Royalty Pharma investors own include Twitter (TWTR), Bausch Health Companies (BHC), NVIDIA (NVDA), (RLYP) (RLYP), Aeterna Zentaris (AEZS), Advanced Micro Devices (AMD) and Netflix (NFLX). This page (NASDAQ:RPRX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Royalty Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Royalty Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
